2014 Pharma Sales 
World of DTC Marketing
JANUARY 10, 2022
Pharma companies are flush with cash and looking to make deals, but there are still a lot of small biotech companies that don’t have enough money to launch their products entirely. Adding sales and medical support staff is expensive, not to mention the cost of “marketing” the drug to patients and consumers.
World of DTC Marketing
SEPTEMBER 7, 2022
In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharma companies. It should be a warning to other pharma companies. ” Pharma CEOs are compensated on how their products earn money.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Evolve Your Success
JUNE 28, 2022
In this second segment of a two-part interview, serial entrepreneur Jeff Smith shares how he found his passion and mission through pharmaceutical sales. Pharma Sales To Med Device CEO: The Jeff Smith Story Part 2. Medical sales reps are also seen as a way to be a better resource to their customers. We had clinical papers.
pharmaphorum
DECEMBER 15, 2022
A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening “footprint, R&D and manufacturing investments” in the country. of total sales – under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) introduced in 2019. The increase to 26.5%
World of DTC Marketing
MAY 26, 2021
net revenue for Imbruvica has increased from $492 million in 2014 to $4.3 billion in Imbruvica net revenue from Medicare Part D between 2014 and 2018. Contrary to the stated purpose of the ODA, AbbVie sought orphan drug protections for Humira even though it was a blockbuster drug with billions of dollars in sales each year.
pharmaphorum
SEPTEMBER 5, 2022
The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. Medreich obtained a licence to supply prochlorperazine in January 2014, but did not start to supply the product until late 2017.
European Pharmaceutical Review
JANUARY 18, 2024
In its report on the insomnia market published last month, GlobalData expected that sales for DORAs, which offer a new mechanism of action for the condition, will continue to grow at a CAGR of 8.6 million in sales by 2032. percent sales expected in 2032 within the seven major markets. percent between 2022 and 2032.
Expert insights. Personalized for you.
213 
Let's personalize your content